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ABSTRACT: Herein we report the 2-aminophenol-4-sulfonamide 1 and its ureido derivatives 2−23 as inhibitors of the
carbonic anhydrase (CA, EC 4.2.1.1) enzymes as analogues of the hypoxic tumor phase II entering drug SLC-0111. This
scaffold may determine preferential rotational isomers to selectively interact within the tumor-associated CAs. Most of the
compounds indeed showed in vitro selective inhibition of the tumor associated CA isoforms IX and XII. The most potent
derivative within the series was 11 (KIs of 2.59 and 7.64 nM on hCA IX and XII, respectively), which shares the 4-
fluorophenylureido tail with the clinical candidate. We investigated by means of X-ray crystallographic studies the binding
modes of three selected compounds of this series to CA I. The evaluation of therapeutic efficacy of compound 11 in an
orthotopic, syngeneic model of CA IX-positive breast cancer in vivo showed close matching antitumoral effects and tolerance
with SLC-0111.
■ INTRODUCTION
Carbonic anhydrases (CAs, EC 4.2.1.1) belong to the
metalloenzyme superfamily and were identified more than
seven decades ago.1−8 To date seven genetically distinct and
unrelated CA families have been characterized so far (i.e., α-,
β-, γ-, δ-, ζ-, η-, and θ-CAs), and they all catalyze the reversible
hydration reaction of carbon dioxide to afford bicarbonate and
protons.1−8 This equilibrium is deeply involved in a variety of
processes at cellular as well as at tissue levels, and among these,
the pH homeostasis is the main one.9−12 The relevance of pH
regulation in normal or in hypoxic tumor cells is well
documented.9−13 A plethora of biological entities located on
the cellular biomembranes are directly involved in pH
modulation (i.e., V-ATPases, ion exchangers, monocarboxylate
transporters, Na+/H+ exchangers as the main ones), and
among them the CA IX isoform recently stood up as a
validated drug target.13 CA IX is highly expressed in hypoxic
tumors (i.e., breast malignancies) and is associated with poor
prognosis.14−17 Conversely to other research groups, which
focused on the development of human (h) CA IX antibodies,18
we turned our attention toward the identification of selective
hCA IX small molecule inhibitors.19 Surprisingly the insertion
of the ureido moiety as a linker between the sulfonamide hCA
inhibitor (CAI) warhead and the molecular tail acted as the
turning point in our extensive medicinal chemistry inves-
tigations within this field.19,20 We demonstrated, by means of
in vitro kinetic studies and X-ray crystal adducts, that the
ureido group allowed higher degrees of flexibility between the
two interconnected sections when compared to previous
investigated linkers of the carboxyamido or of the sulfonamide
type, thus allowing the entire molecule to better allocate within
the enzymatic CA cavities.20 Among the large series of
compounds of this type synthesized, SLC-0111 (also named
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U-104, MST-104, and WBI-5111 in Figure 1) showed high
affinity toward the tumor associated hCA IX in vitro and
promising antiproliferative and antimetastatic properties in in
vivo breast cancer models.13 Such data granted SLC-0111
entering phase II clinical trials for the treatment of advanced
solid tumors.21
Many contributions in the literature reported CAIs
analogues of the SLC-0111 type, and among others, it is
worth mentioning the thioureido,22 the sulfamate,23 and, very
recently, the selenoureido analogues.24 Derivatives of SLC-
0111 bearing the 19F or the 11CO isotopes for imaging
purposes were also synthesized.25,26
In the search of more effective hCA IX selective inhibitors of
the SLC-0111 type, we report for the first time a series of
ureido containing compounds based on the 2-aminophenol-4-
sulfonamide 1. In this study, we explored their in vitro
inhibition data on the physiologically relevant hCAs (i.e., I, II,
IX, and XII), we determined the binding modes of selected
ones by means of X-ray experiments on the hCA I-ligand
adducts, and, finally, we assessed their antitumor properties in
vivo using an orthotopic, syngeneic CA IX-positive breast
tumor model in comparison to SLC-0111.
■ RESULTS AND DISCUSSION
Drug Design and Synthesis. We considered developing
our ureido-containing compound synthetic strategy on the 2-
aminophenol-4-sulfonamide 1 scaffold, whose phenolic OH
was primarily intended to form a stable intramolecular five-
membered ring with the ureido NH moiety placed at the
position 2. The introduction of such a moiety was thought to
induce a rotational restriction between C2 and N1′, which may
determine preferential rotational isomers to interact within the
hCAs enzymatic sites, thus resulting in enhancement of CAs
enzymatic selectivity (Figure 2).
Additionally, the formation of an intramolecular ring, as
discussed above, represents a means to selectively downtune
only the C2−N1′ bond frequency rotation without affecting
the rotational freedom of the remaining scaffold. Our
theoretical considerations on the formation of the intra-
molecular five-membered ring were supported by a com-
parative 1H NMR structural characterization on compound 11
(as the structural analogue of SLC-0111) and its 4-
unsubstituted analogue 11′ previously reported by our
group27,28 (Figure 3).
According to the 400 MHz 1H NMR experiment at 23 °C in
DMSO-d6, the 1′-H, 3′-H and OH in 11 were assigned to the
broad singlet peaks, all exchangeable with D2O, centered at δ
9.46, 8.37, and 10.91 respectively. The 1H NMR experiment of
11′ in the same conditions revealed that the 1′-H and 3′-H
were at δ 9.04 and 8.78 respectively. The δ 0.42 downfield
difference between 11 and 11′ 1′-H was ascribed to the
formation of the intramolecular hydrogen bond interaction.
The insertion of structural modifications within small
molecules greatly affect their solubility properties in aqueous
media, which represents one of the major concerns in early
stages of drug development, as it seriously affects their
bioavailability. Usually the enhancement of water solubility
properties of a drug parallels the increase of the dissolution rate
in the same medium. This kinetic parameter has important
implications mainly on first-pass metabolism and susceptibility
of the drug to efflux mechanisms, which in turn affects
pharmacological effectiveness and patient compliance. There-
fore, we compared the solubility of SLC-0111 and 11 at room
temperature (r.t.) using a spectrophotometric method at the
maximum absorbance of 217 nm, which revealed that the latter
was only slightly less soluble (1.66 fold) in aqueous pH 7.4
buffer solution. This data suggested that the structural
modification introduced in our series (i.e., 2-aminophenol-4-
sulfonamide 1 scaffold) did not significantly affect one of the
main parameters of druggability, at least for these closely
related SLC-0111 derivative.
The synthetic plan adopted for the synthesis of compounds
2−23 consisted of coupling 1 with commercially available
isocyanates using acetonitrile as solvent and according to our
previously reported procedures (Scheme 1).19,20,27,28
All compounds obtained were properly characterized by
means of 1H-, 13C-, and 19F-NMR spectroscopy and HRMS
and were ≥95% HPLC pure (see Experimental Section for
details).
CA Inhibition. We investigated here the CA inhibitory
properties of our reported compounds 1−23, and the obtained
results were compared to the clinically used drug acetazola-
Figure 1. Structure of SLC-0111.
Figure 2. Formation of the intramolecular hydrogen bond leading to a
five-membered ring in the target compounds may lead to C2−N1′
rotational restriction.
Figure 3. 1H NMR 400 MHz signals at 23 °C in DMSO-d6 of
compounds 11 and 11′.
Scheme 1. General Synthesis of 2-Ureidosubstituted
Benzenesulfonamides 2−2319,20,27,28
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mide (AAZ), used as standard CAI, against four physiological
relevant isoforms (i.e., hCAs I, II, IX, and XII) by means of the
stopped flow CO2 hydrase assay.
29
The following structure−activity relationship (SAR) can be
drawn from the data reported in Table 1:
(i) The cytosolic and kinetically slowest hCA I isoform
was poorly inhibited by all compounds in the series (KIs
255.1−5354.1 nM). The most effective inhibitor among
all was the 2-methoxyphenylureido derivative 20, which
showed comparable potency with the reference CAI
AAZ (KIs of 255.1 and 250.0 nM, respectively). Weaker
inhibition potencies were observed for derivatives 2−5,
7, 9−11, 15, 16, and 23 whose KIs were comprised
between 273.3 to 441.0 nM, whereas the remaining
compounds resulted ineffective against the hCA I (KIs
between 551.8 to 5354.1 nM). It should be noted that
the weakest inhibitor among the series was the amino
unsubstituted compound 1 (KI of 5354.1 nM).
(ii) In analogy to the previous one, the second cytosolic
isoform (i.e., hCA II) was weakly inhibited by most of
the compounds reported. Among the series, the 2,5-
dimethylphenylureido derivative 15 was the most potent
inhibitor (KI of 94.3 nM). A modest decrease of potency
(1.5-fold) was obtained with the 2-methylphenylureido
derivative 7 (KI of 137.0 nM). All remaining compounds
were ineffective inhibitors against the hCA II (see Table
1).
(iii) Better inhibition results were obtained for the
transmembrane and tumor associated isoform hCA IX
(Table 1). As reported above, derivatives 2−6, 8, 15, 16,
19, and 21 showed the lowest inhibitory potencies
among the compounds tested with KI values in the range
of 134.1−329.5 nM, thus far less potent when compared
to the reference CAI AAZ (KI of 25.0 nM). Interestingly
the unsubstituted 1 as well as its derivatives 7, 14, 17,
18, 20, and 22 showed remarkable potencies and
comparable to the standard AAZ (KI values comprised
between 19.9 and 26.1 nM). The introduction of the 2-
chloro, 4-nitro, and 1-naphthylureido substituents into
the 3-amino-4-hydroxybenzenesulfonamide 1 scaffold
(compounds 10, 12, and 23) determined a clear
enhancement of the inhibitory potencies against the
hCA IX (KIs of 14.2, 13.9, and 12.3 nM, respectively).
Finally, compounds 9, 11, and 13 were the most potent
inhibitors within the series tested against the IX isoform
(KIs of 2.9, 2.6, and 2.6 nM, respectively), and they
deserve deeper SAR considerations. Among the
chlorophenylureido substituted derivatives 8−10, com-
pound 9 (which is the most active) possess the halogen
in meta position, whereas the introduction of the chloro
Table 1. Inhibition Data of Human CA Isoforms hCA I, II, IX, and XII with Sulfonamides 1−23 and the Acetazolamide (AAZ)
by a Stopped Flow CO2 Hydrase Assay
29
KI (nM)*
compd R hCA I hCA II hCA IX hCA XII
1 5354.1 3333.8 26.1 6.0
2 cyclopentyl 354.0 >10000 254.1 5.5
3 phenethyl 409.3 1647.7 231.4 6.9
4 C6H5CH2 378.6 2343.9 216.1 5.5
5 4-MeC6H4CH2 273.3 667.8 262.5 5.7
6 C6H5 825.3 1394.7 169.0 44.1
7 2-MeC6H4 309.3 136.9 19.9 43.5
8 4-ClC6H4 1434.0 997.6 205.6 6.6
9 3-ClC6H4 377.1 1253.5 2.9 7.1
10 2-ClC6H4 323.1 368.7 14.2 3.0
11 4-FC6H4 441.0 1107.5 2.6 7.6
12 4-NO2C6H4 2493.0 2103.1 13.9 8.0
13 2-NO2−C6H4 2079.8 >10000 2.6 7.8
14 3,5-Me2C6H3 2476.5 7290.5 25.8 5.8
15 2,5-Me2C6H3 306.1 94.3 329.5 48.0
16 2-i-PrC6H4 345.8 762.3 179.7 44.7
17 3-MeSC6H4 739.0 728.5 23.6 35.9
18 4-EtC6H4 665.6 771.7 26.3 57.8
19 4-n-BuC6H4 551.8 3406.2 157.0 5.2
20 2-MeOC6H4 255.1 951.3 23.2 7.3
21 2-EtOC6H4 654.3 373.2 134.1 9.6
22 4-PhOC6H4 2262.9 4416.5 31.0 69.0
23 1-naphthyl 344.5 842.3 12.3 8.7
SLC-0111b 5080 960 45.1 4.5
AAZ 250.0 12.0 25.0 5.7
aMean from three different assays, by a stopped flow technique (errors were in the range of ±5−10% of the reported values). bFrom ref 19.
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in ortho or in para clearly reduced the inhibition
potencies against the hCA IX of 4.9- and 70.9-fold,
respectively. Fluctuations of the kinetic properties in a
regioisomer-dependent manned were also observed for
compounds 12 and 13. Shift of the nitro moiety from
para (compound 12) to ortho to afford the derivative 13
resulted in a 5.3-fold enhancement of the inhibitory
potencies and thus obtaining the second most potent
inhibitor against the hCA IX within the entire series (see
Table 1).
As reported above in Table 1, compounds 11 and 13 match
each other in terms of inhibition potency against the hCA IX
(KIs of 2.6 nM) but presented quite different substitution
patterns. Specifically, compound 11 contains the 4-fluorophe-
nylureido moiety in analogy to SLC-0111. Interestingly, the
latter was 17.3-fold less potent against the hCA IX when
compared to 11.
(iv) The second tumor associated isoform (i.e., hCA
XII) was weakly inhibited by derivatives 6, 7, 15−18,
and 22, which showed KIs spanning between 35.9 and
69.0 nM. Conversely, the remaining derivatives in the
series were far more potent, with KIs in the low
nanomolar range comparable to the standard AAZ. As
reported in Table 1, the inhibition data of these
compounds were similar to each other, thus not allowing
to draw detailed SAR data.
In summary, we reported for the first time the in vitro
inhibitory activity of 2-aminophenol-4-sulfonamide 1 and its
phenylureido derivatives 2−23. Overall, the entire series
showed preferential inhibition of the tumor associated isoforms
hCA IX and XII over the cytosolic, and herein considered, off-
target hCA isoforms I and II. Only compound 15 resulted to
be an inhibitor of hCA II even if the KI value was rather high
(94.3 nM). Of particular interest in this study is a comparative
analysis of the inhibition values relative to compound 11 over
SLC-0111, which share the same 4-fluorophenylureido tail. As
reported in Table 1, 11 was 11.5- and 17.4-fold more effective
when compared to SLC-0111 in inhibiting hCA I and IX,
respectively, whereas it showed KI values 11.5- and 1.7-fold
lower for the cytosolic hCA II and for the second tumor
associated XII. The calculated selectivity indexes (KIhCAII/
KIhCAIX and KIhCAII/KIhCAXII) for SLC-0111 were 21.3 and
213.3, respectively, whereas for its structural analogue 11, 426
and 145.7. Thus, our new compound was more effective in
inhibiting the tumor associated isoform IX when compared to
SLC-0111. Therefore, in consideration of the inhibition data
reported above we consider compound 11 worth to be further
investigated, as an SLC-0111 analogue.
X-ray Crystallography. We assessed the binding modes of
compounds 5, 15, and 20 within the hCA I active site by
means of X-ray crystallographic experiments. Among the series
reported, these compounds were the most active in vitro in
inhibiting the hCA I isoform. In this study, we particularly
focused on the hCA isoform I since the largest majority of X-
ray crystal adducts reported in this field is related to the
ubiquitous hCA II or to the tumor associated IX mimic,30 but
hCA I is very abundant in red blood cells (at 1 μM
concentrations level) and may influence the pharmacokinetics
of drugs interacting with it or other CA isoforms of
pharmacological interest.
As reported below in Figure 4, all compounds were
coordinated to the Zn(II) ion by means of the deprotonated
sulfonamide moiety, which in turn is also engaged in a strong
H-bond with the OH of Thr199 residue. One of the
sulfonamide oxygen is also involved in a hydrogen interaction
with the amide nitrogen of Thr199. This coordination pattern,
which is typical for all primary sulfonamides, is respected also
in these cases.30
Slight differences of the allocated inhibitors within the
enzymatic cavity were observed when a superimposition of the
three structures was performed (Figure 5).
As reported above, 15 and 20 superimpose almost perfectly,
whereas 5 (the only one with an additional CH2 moiety in the
tail) showed a different orientation. Surprisingly, the insertion
Figure 4. Active site region in the hCA I−5 (A), 15 (B), and 20 (C) complexes. The omit Fo − Fc electron density maps (contoured at 2.0 σ) for
the three inhibitors are also shown. PDB accession codes 6F3B, 6FAF and 6FAG, respectively.
Figure 5. Superimposition of hCA I−5 (light blue), 15 (pink), and 20
(green) adducts.
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of the small CH2 spacer forces the inhibitor 5 to interact
mostly with the hydrophobic part of the CA I active site cavity.
Deeper structural considerations of the hCA I-15 and 20
adducts revealed the aromatic rings of the sulfamoylphenyl
heads making hydrophobic contacts with residues Phe91,
Ala121, and Leu198 and a T-shaped stacking with His94.
Additional hydrogen bonding interactions occurred between
the phenoxy and the N1′-ureido moieties with Gln92 and
His67, respectively. As for the inhibitor 20 (the most active in
inhibiting the hCA I), the 2′-methoxy substituent resulted
engaged in additional hydrophobic interaction with Leu198.
The main interactions for the sulfamoylphenyl head of
compound 5 were the hydrophobic contacts with Leu198 and
a parallel π-stacking with His200. The OH on the aromatic
ring formed a water-bridged linkage with Pro201 and N1′ of
the ureido group with Gln92. The 4′-methylphenyl moiety of
the same inhibitor was also engaged by means of hydrophobic
contacts with Ala135 and Pro202.
Although the tumor-associated hCA IX active site differs
from the off-target hCAs I and II isoforms for the higher
hydrophobic amino acidic content, it is interesting to note that
the KI values of 5 relative to these isoforms are all of the same
order of magnitude, whereas compounds 15 and 20 showed
high affinity for the hCA II and IX isoform, respectively. This is
somehow unexpected since the crystallographic analysis
revealed that the extra methylene group in 5 pushes the
molecule toward the hydrophobic section of the CA cleft.
Superpositions of the active sites of the complex hCA I-5 with
those of hCA II and IX also revealed that important mutations
such as Val131/Phe131 (hCA IX/II), Leu91/Phe91, and
Ala204/Tyr204 (hCA IX/I) are present (see Figure 6).
Effect of Compound 11 on Primary Breast Tumor
Growth and Comparison to SLC-0111. The effect of
sulfonamide compound 11 on tumor growth in vivo was
investigated using the orthotopic, syngeneic 4T1 model of
breast cancer, and the obtained results were compared to
treatment of similar tumors with SLC-0111, which shares the
same 4-fluorophenylureido tail. Importantly, 4T1 mouse
tumors demonstrate robust hypoxia-induced expression of
CA IX, and this model has been used previously to evaluate
CA IX inhibitors, including sulfonamides13a and glycosyl
coumarins.13b 4T1 murine breast tumor cells were inoculated
into the mammary fat pad of BALB/c mice and treatments
were initiated after tumors were established (arrows in Figure
7). Both the observed tumor volumes and the volume range at
which treatments were initiated are similar to those reported in
published studies evaluating CA IX inhibitors in this tumor
model.13 Compounds were administered daily by intra-
peritoneal injection, and caliper measurements were used to
monitor tumor growth. As reported below in Figure 7A,
treatment of animals with increasing concentrations of 11
evoked dose-dependent inhibition of tumor growth, with a
maximum effect at 100 mg/kg. A comparison of the reduction
in tumor growth in animals treated with equivalent doses of 11
or SLC-0111 showed nearly superimposable responses (Figure
7B), demonstrating that both compounds were similarly
efficacious in vivo.
Additionally, no significant weight reduction was observed
for any of the treated animals at the concentrations and the
dosing schedules of compound 11 in our experiments, thus
demonstrating that, in analogy to SLC-0111, compound 11 is
well-tolerated in vivo at doses that are therapeutically active
(Figure 8).
■ CONCLUSIONS
We report here a series of sulfonamides, compound 1 and its
derivatives 2−23, possessing aromatic/aliphatic ureido tails,
and they were assayed in vitro on hCA I, II, IX, and XII
isoforms. Almost all compounds showed selective inhibitory
potencies against the tumor associated isoforms hCA IX and
XII except for the compound 15, which showed a 3.49-fold
selectivity on hCA II (KI of 94.29 nM) over IX. The most
effective inhibitors (i.e., with KIs in the low nanomolar range)
of hCA IX were 4-fluorophenyl 11 (KI of 2.59 nM), 2-
nitrophenyl 13 (KI of 2.61 nM), and 3-chlorophenyl 9 (KI of
2.85 nM). In particular, the SLC-0111 structural analogue (i.e.,
compound 11) showed a better selectivity profile against the
hCA IX, thus giving support to our design strategy for the
obtainment of compounds with controlled degrees of tail
flexibility. We reported the binding modes of selected
compounds 5, 15, and 20 in adduct with hCA I, which
revealed the classical coordination pattern within the hCA
cavity. Superposition of the three structures showed that the 5
inhibitor tail, contrarily to compounds 15 and 20, was oriented
toward the hydrophobic part of the cavity. Finally, we
investigated the antitumor activity of compound 11 in vivo
using an orthotopic syngeneic breast tumor model that
robustly expresses hypoxia-inducible CA IX. We found that
compound 11 dose-dependently inhibited tumor growth to
levels that matched those observed with SLC-0111 treatment
and was also associated with an absence of adverse effects
similar to SLC-0111.
■ EXPERIMENTAL SECTION
Materials and Reagents. All anhydrous solvents and reagents
used in this study were purchased from Alfa Aesar, TCI, and Sigma-
Aldrich. The synthetic reactions involving air- or moisture-sensitive
chemicals were carried out under a nitrogen atmosphere using dried
glassware and syringe techniques in order to transfer the solutions.
Nuclear magnetic resonance (1H-, 13C-, and 19F-NMR) spectra were
recorded using a Bruker Advance III 400 MHz spectrometer using
DMSO-d6 as solvent. The chemical shifts are reported in parts per
Figure 6. Superimposition of the active site of the complex hCAI-5
(pale brown) with those of hCAII (green) and hCAIX (salmon).
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million (ppm), and the coupling constants (J) are expressed in Hertz
(Hz). The splitting patterns are designated as s, singlet; d, doublet; t,
triplet; q, quartet; m, multiplet; brs, broad singlet; dd, doublet of
doublets. The correct assignment of exchangeable protons (i.e., OH
and NH) was carried out by means of the addition of D2O. Analytical
thin-layer chromatography (TLC) was done on Merck silica gel F-254
plates. Flash chromatography was performed on Merck Silica gel 60
(230−400 mesh ASTM) as the stationary phase, and appropriate
mixtures of ethyl acetate/n-hexane were the eluents. Melting points
(m.p.) were measured in open capillary tubes with a Gallenkamp
MPD350.BM3.5 apparatus and are uncorrected. The HPLC was
performed by using a Waters 2690 separation module coupled with a
photodiode array detector (PDA Waters 996) using a Nova-Pak C18
4 μm 3.9 mm × 150 mm (Waters) silica-based reverse phase column.
The sample was dissolved in 10% acetonitrile/H2O and an injection
volume of 45 μL. The mobile phase (flow rate 1.0 mL/min) was a
gradient of H2O + trifluoroacetic acid (TFA) 0.1% (A) and
acetonitrile + TFA 0.1% (B), with steps as follows: (A%/B%), 0−
10 min 90:10, 10−25 min gradient to 60:40, 26:28 min isocratic
20:80, 29−35 min isocratic 90:10. TFA 0.1% in water as well in
acetonitrile was used as counterion. All compounds reported here
were ≥95% HPLC pure. The solvents used in MS measures were
acetone, acetonitrile (Chromasolv grade), and mQ water 18 MU. The
high resolution mass spectrometry (HRMS) analysis was performed
with a Thermo Finnigan LTQ Orbitrap mass spectrometer coupled
with an electrospray ionization source (ESI). Analysis was carried out
in positive ion mode [M + H]+, and it was used a proper dwell time
acquisition to achieve 60,000 units of resolution at full width at half-
maximum (fwhm). Elemental composition of compounds was
calculated on the basis of their measured accurate masses, accepting
only results with an attribution error less than 5 ppm and a not integer
RDB (double bond/ring equivalents) value.31 Stock solutions of
analytes were prepared using acetone (1.0 mg mL−1) and stored at 4
°C. Then working solutions of each analyte were prepared by dilution
of the stock solutions using mQ H2O/acetonitrile 1/1 (v/v) up to a
concentration of 1.0 μg mL−1. The HRMS analysis was performed by
introducing the analyte working solution via syringe pump at 10 μL
min−1.
Synthesis of Compounds. General Procedure for the Synthesis
of Compounds 2−23. A solution of 2-aminophenol-4-sulfonamide 1
(0.2 g, 1.0 equiv) in dry acetonitrile (3−4 mL) was treated with a
proper aromatic/aliphatic isocyanate (1.0 equiv). The reaction
mixture was stirred at rt until the consumption of starting materials
(TLC monitoring). Reaction was quenched with H2O and treated
accordingly to afford the compounds 2−23.
Synthesis of 3-(3-Cyclopentylureido)-4-hydroxybenzenesulfona-
mide (2). A solution of 2-aminophenol-4-sulfonamide 1 (0.2 g, 1.0
equiv) in dry acetonitrile (4 mL) was treated with cyclopentyl
isocyanate (1.0 equiv) according to the reported general procedure.
The reaction was quenched with H2O (1.0 mL) to give precipitates
that were washed with diethyl ether (3 × 5 mL), filtered, and dried
under vacuum to afford the titled product 2 as a pale brown solid.
Yield 44%; silica gel TLC Rf 0.28 (MeOH/DCM 10% v/v); mp 195−
196 °C; δH (400 MHz, DMSO-d6) 1.40 (2H, m, Cp), 1.59 (2H, m,
Cp), 1.67 (2H, m, Cp), 1.87 (2H, m, Cp), 3.97 (1H, m, Cp), 6.90
(1H, d, J 8.4, Ar−H), 6.99 (1H, d, J 6.8, exchangeable with D2O,
NH), 7.07 (2H, s, exchangeable with D2O, SO2NH2), 7.25 (1H, dd, J
2.4, 8.4, Ar−H), 7.98 (1H, s, exchangeable with D2O, NH), 8.59 (1H,
d, J 2.4, Ar−H), 10.70 (1H, s, exchangeable with D2O, OH); δC (100
Figure 7. Inhibition of tumor growth after treatment of mice harboring 4T1 tumors with compound 11 and SLC-0111 at diverse dosages. Data
show the mean ± SEM, N = 6 to 8 animals/group. **P < 0.01. (B). Data show the mean ± SEM, N = 6 to 7 animals/group. **P < 0.01, ***P <
0.001.
Figure 8. Spider plots showing body weights for individual animals treated with vehicle, 11, and SLC-0111 as indicated. Both compounds were
well-tolerated by the animals at the doses tested.
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MHz, DMSO-d6) 24.1, 33.7, 51.8, 114.4, 116.5, 119.9, 129.6, 135.7,
148.8, 155.6; m/z (ESI positive) 300.0 [M + H]+.
S yn th e s i s o f 4 -H yd r o x y - 3 - ( 3 - ph en e t h y l u r e i d o ) -
benzenesulfonamide (3). A solution of 2-aminophenol-4-sulfona-
mide 1 (0.2 g, 1.0 equiv) in dry acetonitrile (3 mL) was treated with
phenethyl isocyanate (1.0 equiv) according to the reported general
procedure. The reaction was quenched with H2O (1.0 mL) to give
precipitates that were washed with diethyl ether (3 × 5 mL), filtered,
and dried under vacuum to afford the titled product 3 as a light brown
solid. Yield 42%; silica gel TLC Rf 0.37 (MeOH/DCM 10% v/v); mp
199−200 °C; δH (400 MHz, DMSO-d6) 2.79 (2H, t, J 6.4, CH2), 3.38
(2H, m, CH2), 6.91 (1H, d, J 8.4, Ar−H), 6.99 (1H, t, J 6.4,
exchangeable with D2O, NH), 7.07 (2H, s, exchangeable with D2O,
SO2NH2), 7.33 (6H, m, Ar−H), 8.13 (1H, s, exchangeable with D2O,
NH), 8.60 (1H, d, J 2.4, Ar−H), 10.68 (1H, s, exchangeable with
D2O, OH); δC (100 MHz, DMSO-d6) 36.7, 41.5, 114.6, 116.8, 120.1,
127.0, 129.3, 129.5, 129.6, 135.7, 140.5, 148.9, 156.0; m/z (ESI
negative) 334.0 [M − H]−.
Synthesis of 3-(3-Benzylureido)-4-hydroxybenzenesulfonamide
(4). A solution of 2-aminophenol-4-sulfonamide 1 (0.2 g, 1.0 equiv) in
dry acetonitrile (3 mL) was treated with benzyl isocyanate (1.0 equiv)
according to the reported general procedure. The reaction was
quenched with H2O (1.0 mL) to give precipitates that were washed
with diethyl ether (3 × 5 mL), filtered, and dried under vacuum to
afford the titled product 4 as a pale brown solid. Yield 76%; silica gel
TLC Rf 0.26 (MeOH/DCM 10% v/v); mp 196−197 °C; δH (400
MHz, DMSO-d6) 4.34 (2H, d, J 6.0, CH2), 6.91 (1H, d, J 8.4. Ar−H),
7.09 (2H, s, exchangeable with D2O, SO2NH2), 7.26−7.40 (6H, m,
Ar−H), 7.44 (1H, t, J 6.0, exchangeable with D2O, NH), 8.21 (1H, s,
exchangeable with D2O, NH), 8.62 (1H, d, J 2.4, Ar−H), 10.74 (1H,
s, exchangeable with D2O, OH); δC (100 MHz, DMSO-d6) 43.6,
114.5, 116.7, 120.2, 127.7, 128.1, 129.3, 129.4, 135.7, 141.1, 149.0,
156.1; m/z (ESI positive) 322.0 [M + H]+.
Synthesis of 4-Hydroxy-3-(3-(4-methylbenzyl)ureido)-
benzenesulfonamide (5). A solution of 2-aminophenol-4-sulfona-
mide 1 (0.2 g, 1.0 equiv) in dry acetonitrile (3 mL) was treated with
4-methylbenzyl isocyanate (1.0 equiv) according to the reported
general procedure. The reaction was quenched with H2O (1.0 mL) to
give precipitates that were washed with diethyl ether (3 × 5 mL),
filtered, and dried under vacuum to afford the titled product 5 as a
pale brown solid. Yield 75%; silica gel TLC Rf 0.28 (MeOH/DCM
10% v/v); mp 190−191 °C; δH (400 MHz, DMSO-d6) 2.32 (3H, s,
CH3), 4.29 (2H, d, J 5.6, CH2), 6.91 (1H, d, J 8.4, Ar−H), 7.09 (2H,
s, exchangeable with D2O, SO2NH2), 7.18 (2H, d, J 8.0, Ar−H), 7.22
(2H, d, J 8.0, Ar−H), 7.26 (1H, dd, J 2.4, 8.4, Ar−H), 7.38 (1H, t, J
5.6, exchangeable with D2O, NH), 8.19 (1H, s, exchangeable with
D2O, NH), 8.61 (1H, d, J 2.4, Ar−H), 10.74 (1H, s, exchangeable
with D2O, OH); δC (100 MHz, DMSO-d6) 21.6, 43.4, 114.5, 116.8,
120.2, 128.1, 129.4, 129.8, 135.7, 136.7, 138.0, 149.0, 156.0; m/z (ESI
negative) 334.0 [M − H]−.
Synthesis of 4-Hydroxy-3-(3-phenylureido)benzenesulfonamide
(6). A solution of 2-aminophenol-4-sulfonamide 1 (0.2 g, 1.0 equiv) in
dry acetonitrile (4 mL) was treated with phenyl isocyanate (1.0
equiv) according to the reported general procedure. The reaction was
quenched with H2O (1.0 mL) to give precipitates that were washed
with diethyl ether (3 × 5 mL), filtered, and dried under vacuum to
afford the titled product 6 as a pale brown solid. Yield 67%; silica gel
TLC Rf 0.25 (MeOH/DCM 10% v/v); mp 223−224 °C (dec); δH
(400 MHz, DMSO-d6) 6.99 (2H, m, Ar−H), 7.13 (2H, s,
exchangeable with D2O, SO2NH2), 7.32 (3H, m, Ar−H), 7.50 (2H,
d, J 8.0, Ar−H), 8.39 (1H, s, exchangeable with D2O, NH), 8.68 (1H,
d, J 2.4, Ar−H), 9.41 (1H, s, exchangeable with D2O, NH), 10.87
(1H, s, exchangeable with D2O, OH); δC (100 MHz, DMSO-d6)
114.5, 116.9, 118.9, 120.8, 122.8, 128.8, 129.8, 135.8, 140.6, 149.2,
153.2; m/z (ESI negative) 306.0 [M − H]−.
Synthesis of 4-Hydroxy-3-(3-(o-tolyl)ureido)benzenesulfonamide
(7). A solution of 2-aminophenol-4-sulfonamide 1 (0.2 g, 1.0 equiv) in
dry acetonitrile (3 mL) was treated with 2-methylphenyl isocyanate
(1.0 equiv) according to the reported general procedure. The reaction
was quenched with H2O (1.0 mL) to give precipitates that were
washed with diethyl ether (3 × 5 mL), filtered, and dried under
vacuum to afford the titled product 7 as a beige solid. Yield 85%; silica
gel TLC Rf 0.33 (MeOH/DCM 10% v/v); mp 201−202 °C; δH (400
MHz, DMSO-d6) 2.29 (3H, s, CH3), 6.99 (2H, m, Ar−H), 7.18 (4H,
m, 2H exchangeable with D2O, SO2NH2), 7.32 (1H, dd, J 2.4, 8.4,
Ar−H), 7.87 (1H, d, J 8.0, Ar−H), 8.64 (1H, s, exchangeable with
D2O, NH), 8.69 (1H, d, J 2.4, Ar−H), 8.84 (1H, s, exchangeable with
D2O, NH), 10.85 (1H, s, exchangeable with D2O, OH); δC (100
MHz, DMSO-d6) 19.0, 114.6, 117.2, 120.7, 122.4, 123.7, 127.0, 128.8,
129.0, 131.1, 135.7, 138.2, 149.3, 153.6; m/z (ESI positive) 321.9 [M
+ H]+.
Synthesis of 3-(3-(4-Chlorophenyl)ureido)-4-hydroxybenzenesul-
fonamide (8). A solution of 2-aminophenol-4-sulfonamide 1 (0.2 g,
1.0 equiv) in dry acetonitrile (3 mL) was treated with 4-chlorophenyl
isocyanate (1.0 equiv) according to the reported general procedure.
The reaction was quenched with H2O (1.0 mL) to give precipitates
that were washed with diethyl ether (3 × 5 mL), filtered, and dried
under vacuum to afford the titled product 8 as a beige solid. Yield
82%; silica gel TLC Rf 0.29 (MeOH/DCM 10% v/v); mp 223−224
°C (dec); δH (400 MHz, DMSO-d6) 6.98 (1H, d, J 8.4, Ar−H), 7.15
(2H, s, exchangeable with D2O, SO2NH2), 7.33 (1H, dd, J 2.4, 8.4,
Ar−H), 7.37 (2H, d, J 8.8, Ar−H), 7.52 (2H, d, J 8.8, Ar−H), 8.42
(1H, s, exchangeable with D2O, NH), 8.67 (1H, d, J 2.4, Ar−H), 9.55
(1H, s, exchangeable with D2O, NH), 10.93 (1H, s, exchangeable with
D2O, OH); δC (100 MHz, DMSO-d6) 114.6, 116.9, 120.4, 121.0,
126.3, 128.6, 129.7, 135.8, 139.6, 149.3, 153.1; m/z (ESI negative)
339.9 [M − H]−.
Synthesis of 3-(3-(3-Chlorophenyl)ureido)-4-hydroxybenzenesul-
fonamide (9). A solution of 2-aminophenol-4-sulfonamide 1 (0.2 g,
1.0 equiv) in dry acetonitrile (3 mL) was treated with 3-chlorophenyl
isocyanate (1.0 equiv) according to the reported general procedure.
The reaction was quenched with H2O (1.0 mL) to give precipitates
that were washed with diethyl ether (3 × 10 mL), filtered, and dried
under vacuum to afford the titled product 9 as a pale brown solid.
Yield 58%; silica gel TLC Rf 0.28 (MeOH/DCM 10% v/v); mp 235−
236 °C (dec); δH (400 MHz, DMSO-d6) 6.99 (1H, d, J 8.4, Ar−H),
7.06 (1H, m, Ar−H), 7.16 (2H, s, exchangeable with D2O, SO2NH2),
7.25 (1H, m, Ar−H), 7.35 (2H, m, Ar−H), 7.80 (1H, t, J 2.0, Ar−H),
8.45 (1H, s, exchangeable with D2O, NH), 8.67 (1H, d, J 2.4, Ar−H),
9.62 (1H, s, exchangeable with D2O, NH), 10.96 (1H, s, exchangeable
with D2O, OH); δC (100 MHz, DMSO-d6) 114.6, 117.0, 117.3, 118.2,
121.1, 122.4, 128.5, 131.4, 134.2, 135.8, 142.1, 149.3, 153.1; m/z (ESI
positive) 341.9 [M + H]+.
Synthesis of 3-(3-(2-Chlorophenyl)ureido)-4-hydroxybenzenesul-
fonamide (10). A solution of 2-aminophenol-4-sulfonamide 1 (0.2 g,
1.0 equiv) in dry acetonitrile (4 mL) was treated with 2-chlorophenyl
isocyanate (1.0 equiv) according to the reported general procedure.
The reaction was quenched with H2O (1.0 mL) to give precipitates
that were washed with diethyl ether (3 × 10 mL), filtered, and dried
under vacuum to afford the titled product 10 as a beige solid. Yield
80%; silica gel TLC Rf 0.33 (MeOH/DCM 10% v/v); δH (400 MHz,
DMSO-d6) 6.99 (1H, d, J 8.4; Ar−H), 7.08 (1H, dt, J 1.2, 8.0, Ar−H),
7.15 (2H, s, exchangeable with D2O, SO2NH2), 7.34 (2H, m, Ar−H),
7.49 (1H, dd, J 1.2, 8.0, Ar−H), 8.15 (1H, dd, J 1.2, 8.0, Ar−H), 8.66
(1H, d, J 2.4, Ar−H), 9.10 (1H, s, exchangeable with D2O, NH), 9.22
(1H, exchangeable with D2O, NH), 10.88 (1H, exchangeable with
D2O, OH); δC (100 MHz, DMSO-d6) 114.8, 117.7, 121.3, 123.2,
123.6, 124.6, 128.4, 128.6, 130.3, 135.7, 137.0, 149.8, 153.4; m/z (ESI
negative) 339.9 [M − H]−.
Synthesis of 3-(3-(4-Fluorophenyl)ureido)-4-hydroxybenzenesul-
fonamide (11). A solution of 2-aminophenol-4-sulfonamide 1 (0.2 g,
1.0 equiv) in dry acetonitrile (3 mL) was treated with 4-fluorophenyl
isocyanate (1.0 equiv) according to the reported general procedure.
The reaction was quenched with H2O (1.0 mL) and extracted with
ethyl acetate (3 × 15 mL). The combined organic layers were washed
with H2O (3 × 20 mL), dried over Na2SO4, filtered, and concentrated
under vacuum to give the titled product 11 as a beige solid. Yield
86%; silica gel TLC Rf 0.28 (MeOH/DCM 10% v/v); mp 230−231
°C (dec); δH (400 MHz, DMSO-d6) 6.97 (1H, d, J 8.4, Ar−H), 7.16
(4H, m, 2H exchangeable with D2O, SO2NH2), 7.32 (1H, dd, J 2.4,
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8.4, Ar−H), 7.50 (2H, m, Ar−H), 8.37 (1H, s, exchangeable with
D2O, NH), 8.66 (1H, d, J 2.4, Ar−H), 9.46 (1H, s, exchangeable with
D2O, NH), 10.91 (1H, s, exchangeable with D2O, OH); δC (100
MHz, DMSO-d6) 114.6, 116.3 (d,
2JC−F 22), 116.9, 120.5 (d,
3JC−F 8),
120.9, 128.8, 135.8, 137 (d, 4JC−F 2), 149.2, 153.3, 158.3 (d,
1JC−F
237); δF (376 MHz, DMSO-d6) −121.4 (1F, s); m/z (ESI negative)
324.0 [M − H]−.
Synthesis of 4-Hydroxy-3-(3-(4-nitrophenyl)ureido)-
benzenesulfonamide (12). A solution of 2-aminophenol-4-sulfona-
mide 1 (0.2 g, 1.0 equiv) in dry acetonitrile (4 mL) was treated with
4-nitrophenyl isocyanate (1.0 equiv) according to the reported
general procedure. The reaction was quenched with H2O (1.0 mL) to
give precipitates that were washed with diethyl ether (3 × 10 mL),
filtered, and dried under vacuum to afford the titled product 12 as a
pale brown solid. Yield 75%; silica gel TLC Rf 0.33 (MeOH/DCM
10% v/v); mp 258−259 °C (dec); δH (400 MHz, DMSO-d6) 6.99
(1H, d, J 8.4, Ar−H), 7.17 (2H, s, exchangeable with D2O, SO2NH2),
7.37 (1H, dd, J 2.4, 8.4, Ar−H), 7.74 (2H, d, J 9.2, Ar−H), 8.24 (2H,
d, J 9.2, Ar−H), 8.62 (1H, s, exchangeable with D2O, NH), 8.68 (1H,
d, J 2.4, Ar−H), 10.13 (1H, s, exchangeable with D2O, NH), 11.04
(1H, s, exchangeable with D2O, OH); δC (100 MHz, DMSO-d6)
114.8, 117.2, 118.2, 121.6, 126.2, 128.1, 135.8, 142.0, 147.2, 149.5,
152.7; m/z (ESI negative) 350.9 [M − H]−.
Synthesis of 4-Hydroxy-3-(3-(2-nitrophenyl)ureido)-
benzenesulfonamide (13). A solution of 2-aminophenol-4-sulfona-
mide 1 (0.2 g, 1.0 equiv) in dry acetonitrile (3 mL) was treated with
2-nitrophenyl isocyanate (1.0 equiv) according to the reported
general procedure previously reported. The reaction was quenched
with H2O (1.0 mL) to give precipitates that were washed with diethyl
ether (3 × 10 mL), filtered, and dried under vacuum to afford the
titled product 13 as a yellow solid. Yield 77%; silica gel TLC Rf 0.31
(MeOH/DCM 10% v/v); δH (400 MHz, DMSO-d6) 7.00 (1H, d, J
8.4, Ar−H), 7.16 (2H, s, exchangeable with D2O, SO2NH2), 7.29
(1H, t, J 7.2, Ar−H), 7.37 (1H, dd, J 2.4, 8.4, Ar−H), 7.72 (1H, t, J
7.2, Ar−H), 8.06 (2H, m, Ar−H), 8.56 (1H, d, J 2.4, Ar−H), 9.27
(1H, s, exchangeable with D2O, NH), 9.87 (1H, s, exchangeable with
D2O, NH), 10.90 (1H, s, exchangeable with D2O, OH); δC (100
MHz, DMSO-d6) 115.0, 118.2, 121.8, 124.0, 124.9, 126.1, 128.1,
134.4, 135.3, 135.7, 140.6, 150.1, 153.0; m/z (ESI negative) 350.9 [M
− H]−.
Synthesis of 3-(3-(3,5-Dimethylphenyl)ureido)-4-hydroxybenze-
nesulfonamide (14). A solution of 2-aminophenol-4-sulfonamide 1
(0.2 g, 1.0 equiv) in dry acetonitrile (3 mL) was treated with 3,5-
dimethlyphenyl isocyanate (1.0 equiv) according to the reported
general procedure. The reaction was quenched with H2O (1.0 mL) to
give precipitates that were washed with diethyl ether (3 × 10 mL),
filtered, and dried under vacuum to afford the titled product 14 as a
pale brown solid. Yield 81%; silica gel TLC Rf 0.39 (MeOH/DCM
10% v/v); mp 228−229 °C (dec); δH (400 MHz, DMSO-d6) 2.27
(6H, s, 2 x CH3), 6.66 (1H, s, Ar−H), 6.97 (1H, d, J 8.4, Ar−H), 7.13
(4H, m, 2H exchangeable with D2O, SO2NH2), 7.32 (1H, dd, J 2.4,
8.4, Ar−H), 8.38 (1H, s, exchangeable with D2O, NH), 8.69 (1H, d, J
2.4, Ar−H), 9.27 (1H, s, exchangeable with D2O, NH), 10.88 (1H,
brs; exchangeable with D2O, OH); δC (100 MHz, DMSO-d6) 22.1,
114.5, 116.6, 116.8, 120.7, 124.4, 128.9, 135.8, 138.7, 140.5, 149.2,
153.2; m/z (ESI positive) 336.0 [M + H]+.
Synthesis of 3-(3-(2,5-Dimethylphenyl)ureido)-4-hydroxybenze-
nesulfonamide (15). A solution of 2-aminophenol-4-sulfonamide 1
(0.2 g, 1.0 equiv) in dry acetonitrile (3 mL) was treated with 2,5-
dimethylphenyl isocyanate (1.0 equiv) according to the reported
general procedure. The reaction was quenched with H2O (1.0 mL) to
give precipitates that were washed with diethyl ether (3 × 10 mL),
filtered, and dried under vacuum to afford the titled product 15 as a
beige solid. Yield 95%; silica gel TLC Rf 0.22 (MeOH/DCM 10% v/
v); mp 245−246 °C (dec); δH (400 MHz, DMSO-d6) 2.24 (3H, s,
CH3), 2.29 (3H, s, CH3), 6.80 (1H, d, J 8.0, Ar−H), 6.98 (1H, d, J
8.4, Ar−H), 7.08 (1H, d, J 8.0, Ar−H), 7.13 (2H, s, exchangeable with
D2O, SO2NH2), 7.31 (1H, dd, J 2.4, 8.4, Ar−H), 7.73 (1H, s, Ar−H),
8.58 (1H, s, exchangeable with D2O, NH), 8.70 (1H, d, J 2.4, Ar−H),
8.83 (1H, s, exchangeable with D2O, NH), 10.83 (1H, s, exchangeable
with D2O, OH); δC (100 MHz, DMSO-d6) 18.6, 21.9, 114.6, 117.1,
120.7, 122.9, 124.3, 125.6, 129.0, 131.0, 135.8, 135.9, 138.1, 149.3,
153.6; m/z (ESI negative) 334.0 [M − H]−.
Synthesis of 4-Hydroxy-3-(3-(2-isopropylphenyl)ureido)-
benzenesulfonamide (16). A solution of 2-aminophenol-4-sulfona-
mide 1 (0.2 g, 1.0 equiv) in dry acetonitrile (3 mL) was treated with
2-isopropylphenyl isocyanate (1.0 equiv) according to the general
procedure previously reported. The reaction was quenched with H2O
(1.0 mL) to give precipitates that were washed with diethyl ether (3 ×
10 mL), filtered, and dried under vacuum to afford the titled product
16 as a beige solid. Yield 11%; silica gel TLC Rf 0.42 (MeOH/DCM
10% v/v); mp 218−219 °C; δH (400 MHz, DMSO-d6) 1.23 (6H, d, J
6.8, 2 × CH3), 3.25 (1H, m, CH), 6.98 (1H, d, J 8.4, Ar−H), 7.14
(4H, m, 2H exchangeable with D2O, SO2NH2), 7.32 (2H, m, Ar−H),
7.67 (1H, dd, J 1.6, 8.0, Ar−H), 8.66 (1H, s, exchangeable with D2O,
NH), 8.68 (1H, d, J 2.4, Ar−H), 8.77 (1H, s, exchangeable with D2O,
NH), 10.86 (1H, s, exchangeable with D2O, OH); δC (100 MHz,
DMSO-d6) 24.2, 27.6, 114.6, 117.1, 120.7, 125.0, 125.0, 126.2, 126.6,
129.1, 135.7, 136.3, 140.8, 149.3, 154.1; m/z (ESI negative) 348.0 [M
− H]−.
Synthesis of 4-Hydroxy-3-(3-(3-(methylthio)phenyl)ureido)-
benzenesulfonamide (17). A solution of 2-aminophenol-4-sulfona-
mide 1 (0.2 g, 1.0 equiv) in dry acetonitrile (3 mL) was treated with
3-(methylthio)phenyl isocyanate (1.0 equiv) according to the
reported general procedure. The reaction was quenched with H2O
(1.0 mL) to give precipitates that were washed with diethyl ether (3 ×
10 mL), filtered, and dried under vacuum to afford the titled product
17 as a pale brown solid. Yield 56%; silica gel TLC Rf 0.20 (MeOH/
DCM 10% v/v); mp 220−221 °C (dec); δH (400 MHz, DMSO-d6)
2.50 (3H, s, CH3), 6.90 (1H, d, J 8.0, Ar−H), 6.98 (1H, d, J 8.4, Ar−
H), 7.15 (3H, m, 2H exchangeable with D2O, SO2NH2), 7.26 (1H, t,
J 8.0, Ar−H), 7.33 (1H, dd, J 2.4, 8.4, Ar−H), 7.55 (1H, m, Ar−H),
8.40 (1H, s, exchangeable with D2O, NH), 8.67 (1H, d, J 2.4, Ar−H),
9.47 (1H, s, exchangeable with D2O, NH), 10.90 (1H, s, exchangeable
with D2O, OH); δC (100 MHz, DMSO-d6) 15.5, 114.6, 115.4, 115.8,
116.9, 120.2, 120.9, 128.7, 130.3, 135.8, 139.7, 141.2, 149.2, 153.1;
m/z (ESI negative) 352.0 [M − H]−.
Synthesis of 3-[3-(4-Ethyl-phenyl)-ureido]-4-hydroxy-benzene-
sulfonamide (18). A solution of 2-aminophenol-4-sulfonamide 1
(0.2 g, 1.0 equiv) in dry acetonitrile (3 mL) was treated with 4-
ethylphenyl isocyanate (1.0 equiv) according to the reported general
procedure. The reaction was quenched with H2O (1.0 mL) to give
precipitates that were washed with diethyl ether (3 × 10 mL), filtered,
and dried under vacuum to afford the titled product 18 as a beige
solid. Yield 78%; silica gel TLC Rf 0.29 (MeOH/DCM 10% v/v); mp
210−211 °C; δH (400 MHz, DMSO-d6) 1.20 (3H, t, J 7.6, CH3), 2.59
(2H, m, CH2), 6.96 (1H, d, J 8.4, Ar−H), 7.14 (2H, s, exchangeable
with D2O, SO2NH2), 7.16 (2H, d, J 8.4, Ar−H), 7.32 (1H, dd, J 2.4,
8.4, Ar−H), 7.40 (2H, d, J 8.4, Ar−H), 8.36 (1H, s, exchangeable with
D2O, NH), 8.68 (1H, d, J 2.4, Ar−H), 9.33 (1H, s, exchangeable with
D2O, NH), 10.87 (1H, s, exchangeable with D2O, OH); δC (100
MHz, DMSO-d6) 16.7, 28.4, 114.5, 116.8, 119.0, 120.7, 128.9, 129.0,
135.8, 138.2, 138.3, 149.2, 153.3; m/z (ESI negative) 334.0 [M −
H]−.
Synthesis of 3-(3-(4-Butylphenyl)ureido)-4-hydroxybenzenesul-
fonamide (19). A solution of 2-aminophenol-4-sulfonamide 1 (0.2 g,
1.0 equiv) in dry acetonitrile (4 mL) was treated with 4-butylphenyl
isocyanate (1.0 equiv) according to the reported general procedure.
The reaction was quenched with H2O (1.0 mL) to give precipitates
that were washed with diethyl ether (3 × 10 mL), filtered, and dried
under vacuum to afford the titled product 19 as a beige solid. Yield
65%; silica gel TLC Rf 0.74 (ethyl acetate 100% v/v); mp 204−205
°C (dec); δH (400 MHz, DMSO-d6) 0.93 (3H, t, J 7.3, CH3), 1.33
(2H, m, CH2), 1.56 (2H, quint, J 7.3, CH2), 2.56 (2H, m, CH2), 6.96
(1H, d, J 8.4, Ar−H), 7.13 (4H, m, 2H exchangeable with D2O,
SO2NH2), 7.31 (1H, dd, J 2.4, 8.4, Ar−H), 7.39 (2H, d, J 8.4, Ar−H),
8.36 (1H, s, exchangeable with D2O, NH), 8.68 (1H, d, J 2.4, Ar−H),
9.33 (1H, s, exchangeable with D2O, NH), 10.89 (1H, brs,
exchangeable with D2O, OH); δC (100 MHz, DMSO-d6) 14.7,
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22.6, 34.2, 35.1, 114.5, 116.8, 119.0, 120.7, 128.9, 129.5, 135.8, 136.7,
138.3, 149.2, 153.3; m/z (ESI negative) 362.0 [M − H]−.
Synthesis of 4-Hydroxy-3-(3-(2-methoxyphenyl)ureido)-
benzenesulfonamide (20). A solution of 2-aminophenol-4-sulfona-
mide 1 (0.2 g, 1.0 equiv) in dry acetonitrile (3 mL) was treated with
2-methoxyphenyl isocyanate (1.0 equiv) according to the reported
general procedure. The reaction was quenched with H2O (1.0 mL) to
give precipitates that were washed with diethyl ether (3 × 10 mL),
filtered, and dried under vacuum to afford the titled product 20 as a
beige solid. Yield 44%; silica gel TLC Rf 0.28 (MeOH/DCM 10% v/
v); mp 209−210 °C (dec); δH (400 MHz, DMSO-d6) 3.90 (3H, s,
OCH3), 6.90−7.05 (4H, m, Ar−H), 7.13 (2H, s, exchangeable with
D2O, SO2NH2), 7.32 (1H, dd, J 2.4, 8.4, Ar−H), 8.15 (1H, dd, J 1.2,
8.0, Ar−H), 8.66 (1H, d, J 2.4, Ar−H), 9.03 (1H, s, exchangeable with
D2O, NH), 9.10 (1H, s, exchangeable with D2O, NH), 10.75 (1H, s,
exchangeable with D2O, OH); δC (100 MHz, DMSO-d6) 56.6, 111.8,
114.7, 117.7, 120.0, 120.9, 121.4, 123.0, 128.9, 129.6, 135.7, 149.2,
149.8, 153.6; m/z (ESI negative) 336.0 [M − H]−.
Synthesis of 3-(3-(2-Ethoxyphenyl)ureido)-4-hydroxybenzenesul-
fonamide (21). A solution of 2-aminophenol-4-sulfonamide 1 (0.2 g,
1.0 equiv) in dry acetonitrile (4 mL) was treated with 2-ethoxyphenyl
isocyanate (1.0 equiv) according to the reported general procedure.
The reaction was quenched with H2O (1.0 mL) to give precipitates
that were washed with diethyl ether (3 × 10 mL), filtered, and dried
under vacuum to afford the titled product 21 as a beige solid. Yield
80%; silica gel TLC Rf 0.72 (ethyl acetate 100% v/v); mp 208−209
°C (dec); δH (400 MHz, DMSO-d6) 1.45 (3H, t, J 7.0, CH3), 4.16
(2H, q, J 7.0, OCH2), 6.91 (1H, dt, J 1.6, 8.0, Ar−H), 6.97 (2H, m,
Ar−H), 7.03 (1H, dd, J 1.6, 8.0, Ar−H), 7.13 (2H, s, exchangeable
with D2O, SO2NH2), 7.33 (1H, dd, J 2.4, 8.4, Ar−H), 8.13 (1H, dd, J
1.6, 8.0, Ar−H), 8.64 (1H, d, J 2.4, Ar−H), 8.83 (1H, s, exchangeable
with D2O, NH), 9.11 (1H, s, exchangeable with D2O, NH), 10.77
(1H, s, exchangeable with D2O, OH); δC (100 MHz, DMSO-d6) 15.7,
64.8, 112.9, 114.8, 118.0, 120.4, 121.0, 121.3, 123.1, 128.8, 129.8,
135.7, 148.3, 149.9, 153.6; m/z (ESI negative) 350.0 [M − H]−.
Synthesis of 4-Hydroxy-3-(3-(4-phenoxyphenyl)ureido)-
benzenesulfonamide (22). A solution of 2-aminophenol-4-sulfona-
mide 1 (0.2 g, 1.0 equiv) in dry acetonitrile (3 mL) was treated with
4-phenoxyphenyl isocyanate (1.0 equiv) according to the reported
general procedure. The reaction was quenched with H2O (1.0 mL) to
give precipitates that were washed with diethyl ether (3 × 10 mL),
filtered, and dried under vacuum to afford the titled product 22 as a
beige solid. Yield 70%; silica gel TLC Rf 0.20 (MeOH/DCM 10% v/
v); mp 225−226 °C; δH (400 MHz, DMSO-d6) 7.00 (5H, m, Ar−H),
7.14 (3H, m, 2H exchangeable with D2O, SO2NH2), 7.33 (1H, dd, J
2.4, 8.4, Ar−H), 7.40 (2H, m, Ar−H), 7.52 (2H, d, J 8.8, Ar−H), 8.37
(1H, s, exchangeable with D2O, NH), 8.68 (1H, d, J 2.4, Ar−H), 9.44
(1H, s, exchangeable with D2O, NH), 10.89 (1H, exchangeable with
D2O, OH); δC (100 MHz, DMSO-d6) 114.6, 116.9, 118.7, 120.6,
120.8, 120.9, 123.8, 128.9, 130.9, 135.8, 136.7, 149.2, 151.7, 153.3,
158.6; m/z (ESI negative) 398.0 [M − H]−.
Synthesis of 4-Hydroxy-3-(3-(naphthalen-1-yl)ureido)-
benzenesulfonamide (23). A solution of 2-aminophenol-4-sulfona-
mide 1 (0.2 g, 1.0 equiv) in dry acetonitrile (3 mL) was treated with
1-naphthyl isocyanate (1.0 equiv) according to the reported general
procedure. The reaction was quenched with H2O (1.0 mL) to give
precipitates that were washed with diethyl ether (3 × 10 mL), filtered,
and dried under vacuum to afford the titled product 23 as a beige
solid. Yield 84%; silica gel TLC Rf 0.35 (MeOH/DCM 10% v/v); mp
235−236 °C (dec); δH (400 MHz, DMSO-d6) 7.01 (1H, d, J 8.4, Ar−
H), 7.16 (2H, s, exchangeable with D2O, SO2NH2), 7.35 (1H, dd, J
2.4, 8.4, Ar−H), 7.51 (1H, t, J 8.0, Ar−H), 7.60 (2H, m, Ar−H), 7.67
(1H, d, J 8.0, Ar−H), 7.96 (1H, d, J 8.0, Ar−H), 8.11 (1H, d, J 8.0,
Ar−H), 8.26 (1H, d, J 8.0, Ar−H), 8.75 (1H, d, J 2.4, Ar−H), 9.00
(1H, s, exchangeable with D2O, NH), 9.44 (1H, s, exchangeable with
D2O, NH), 10.93 (1H, s, exchangeable with D2O, OH); δC (100
MHz, DMSO-d6) 114.9, 117.3, 118.5, 121.1, 122.6, 124.1, 126.7,
126.9, 127.0, 129.1, 129.5, 134.8, 135.4, 135.9, 149.6, 154.0; m/z (ESI
negative) 356.0 [M − H]−.
In Vitro Enzyme Assays. Carbonic Anhydrase Inhibition. The
CA-catalyzed CO2 hydration activity was performed on an Applied
Photophysics stopped-flow instrument using phenol red (at a
concentration of 0.2 mM) as a pH indicator with 20 mM Hepes
(pH 7.5) as the buffer, 20 mM Na2SO4, and following the initial rates
of the CA-catalyzed CO2 hydration reaction for a period of 10−100 s
and working at the maximum absorbance of 557 nm.29 The CO2
concentrations ranged from 1.7 to 17 mM. For each inhibitor six
traces of the initial 5−10% of the reaction have been used in order to
determine the initial velocity. The uncatalyzed reaction rates were
determined in the same manner and subtracted from the total
observed rates. Stock solutions of inhibitor (0.1 mM) were prepared
in distilled water, and dilutions up to 0.01 nM were prepared.
Solutions containing inhibitor and enzyme were preincubated for 15
min at room temperature prior to assay in order to allow the
formation of the E−I complex. The inhibition constants were
obtained as nonlinear least-squares protocols using PRISM 331−33 and
are the mean from at least three different measurements. All hCAs
were recombinant ones and were obtained in house.31−33
X-ray Crystallography. Crystallization and Data Collection.
Crystals of hCA I complexed with compounds 5, 15, and 20 were
obtained using the sitting drop vapor diffusion method. Two
microliters of 10 mg/mL solution of hCA I in Tris-HCl 20 mM
pH 9.0 were mixed with 2 μL of a solution of 28−31% PEG4000, 0.2
M sodium acetate, and 0.1 M Tris pH 8.5−9.0 and were equilibrated
against the same solution at 296 K. Crystals of the protein grew in 15
days. Afterward, hCA I crystals were soaked in 5 mM inhibitor
solutions for 1 day. The crystals were flash-frozen at 100 K using a
solution obtained by adding 15% (v/v) glycerol to the mother liquor
solution as cryoprotectant. Data on crystals of the complexes were
collected using synchrotron radiation at the ID30B beamline at ESRF
(Grenoble, France) with a wavelength of 0.973 Å and a PILATUS3 6
M Dectris CCD detector. Data were integrated and scaled using the
program XDS.34 Data processing statistics are shown in Supporting
Information Table S1.
Structure Determination. The crystal structure of hCA I (PDB
accession code: 1JV0) without solvent molecules and other
heteroatoms was used to obtain initial phases for the structures
using Refmac5.35 Five percent of the unique reflections were selected
randomly and excluded from the refinement data set for the purpose
of Rfree calculations. The initial |Fo − Fc| difference electron density
maps unambiguously showed the inhibitor molecules. Atomic models
for inhibitors were calculated and energy minimized using the
program JLigand 1.0.40.36 Refinements proceeded using normal
protocols of positional, isotropic atomic displacement parameters
alternating with manual building of the models using COOT.37
Solvent molecules were introduced automatically using the program
ARP.38 The quality of the final models were assessed with COOT and
RAMPAGE.39 Crystal parameters and refinement data are summar-
ized in Table S1 in the Supporting Information. Atomic coordinates
were deposited in the Protein Data Bank (PDB accession code: 6F3B,
6FAF, and 6FAG). Graphical representations were generated with
Chimera.40
Biological Assays. Cell Culture. The 4T1 murine breast cancer
cell line was cultured as previously described.13,41 Briefly, cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
containing 25 mM glucose (Gibco cat # 11995−065, Burlington,
Ontario) and supplemented with 10% fetal bovine serum (FBS;
Gibco, Burlington, Ontario) and nonessential amino acids (1×
NEAA). Cells were routinely tested for mycoplasma contamination
using the LookOut Mycoplasma PCR detection kit (Sigma; Cat. No.
MP0035). The 4T1 cells have been authenticated using short tandem
repeat DNA profiling (DNA fingerprinting) by a commercial testing
facility (Genetica, Burlington, NC, USA). In addition, the cell lines
were routinely tested for viability, morphology, hypoxia-induced
endogenous CA IX expression, and in vivo tumor growth.
Orthotopic Syngeneic Breast Tumor Model. All animal studies
and procedures were performed in accordance with protocols
approved by the Institutional Animal Care Committee at the BC
Cancer Research Centre and University of British Columbia
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(Vancouver, BC, Canada). 4T1 murine mammary tumor cells (1.0 ×
106 cells/animal) were implanted orthotopically into the mammary fat
pad of BALB/c mice (Simonsen Laboratories, Gilroy, CA) as
described previously.13,42 Tumors were measured 3×/week using
digital calipers, and volumes were calculated using the modified
ellipsoid formula ((length × width × width)π/6). Immediately prior
to initiation of treatment, mice were randomized and sorted into
groups of similar average tumor volume. Treatment was initiated
when mean tumor volumes reached approximately 60 mm3.
Drug Treatment. Compound 11 and SLC-0111 were solubilized at
the indicated concentrations in the same vehicle (37.5% PEG-400/
12.5% ethanol/50%PBS), divided into daily aliquots and frozen at
−80 °C until use. Compounds were administered by intraperitoneal
injection daily until the experimental end point. Control animals were
administered the vehicle alone in a similar fashion. The investigators
were not blinded to the treatment groups.
Statistical Analysis. For tumor growth data, statistical analyses
were performed using GraphPad Prism 7. Data are reported as the
mean ± SEM. Outliers were identified using Grubb’s test (alpha =
0.05) and excluded from further analysis. For comparison of three or
more data sets, a one-way ANOVA was performed and a Holms-
Sidak’s test was used to correct for multiple comparisons. Statistical
significance was set at P < 0.05.
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